How to Launch POCT & ELISA IVD Products Under IVDR and FDA 510(k) Compliance

11May 2026

News & Insights IVDCDMO Team Comments: 0

The global in vitro diagnostics (IVD) landscape is governed by two stringent regulatory frameworks: the U.S. Food and Drug Administration (FDA) 510(k) pathway and the European Union’s In Vitro Diagnostic Regulation (IVDR, EU 2017/746). For Point-of-Care Testing (POCT) and Enzyme-Linked Immunosorbent Assay (ELISA) products—mainstays of clinical diagnostics, infectious disease screening, and chronic disease management—achieving dual compliance is critical for accessing the world’s two largest IVD markets (U.S. ~$45B, EU ~$32B; 2025 data).

POCT (e.g., lateral flow assays, rapid immunoassays) and ELISA (e.g., antigen/antibody detection, cytokine quantification) are classified as moderate-risk IVDs under both regimes, requiring rigorous analytical validation, clinical evidence, and quality system alignment. This article provides a step-by-step, data-backed roadmap to navigate FDA 510(k) clearance and IVDR CE marking, with POCT/ELISA-specific considerations, compliance checklists, and timeline benchmarks.

1. Regulatory Classification & Risk Stratification (POCT vs. ELISA)

First, confirm product classification—this dictates submission pathways, data requirements, and timelines.

1.1 FDA Classification (21 CFR Part 862/864)U.S. Food and Drug Administration

POCT IVDs: Class II (90% of cases) → 510(k) clearance required. Examples: rapid COVID-19 antigen tests, HIV antibody screening, cardiac troponin POCT.
ELISA IVDs: Class II → 510(k) clearance required. Examples: infectious disease ELISA kits (HBV/HCV), autoimmune disease panels, tumor marker ELISAs.
Exceptions: High-risk POCT/ELISA (e.g., blood bank screening, companion diagnostics) → Class III → Premarket Approval (PMA) (not covered here).

1.2 IVDR Classification (EU 2017/746, Annex VIII)

IVDR replaces the old IVDD directive (2022 full enforcement) with 4 risk classes (A → D, low → high):

Class A (Low Risk): Self-tests for minor conditions (e.g., pregnancy tests) → Self-declaration (no NB audit).
Class B (Moderate Risk): Most POCT/ELISA (infectious disease, general biomarkers) → Notified Body (NB) audit + CE marking.
Class C (High Risk): Companion diagnostics, critical care POCT → Full NB audit + clinical evidence.
Class D (Highest Risk): Blood safety, transplant diagnostics → EU reference lab assessment + NB audit.

POCT/ELISA Default Classification: Class B (IVDR) + Class II (FDA) → Dual 510(k) + IVDR NB audit pathway.

2. Core Regulatory Requirements: FDA 510(k) vs. IVDR

2.1 FDA 510(k) Essentials (21 CFR 807.92)

The 510(k) is a premarket submission to prove substantial equivalence (SE) to a legally marketed “predicate device” (same intended use, similar tech/performance).

Key 510(k) Requirements for POCT/ELISA

Predicate Device Selection: Choose 1–2 FDA-cleared POCT/ELISA predicates (same analyte, specimen type, intended use). Example: A COVID-19 POCT assay may use the FDA-cleared Abbott BinaxNOW as a predicate.
Analytical Performance Data (Critical for POCT/ELISA):
- Precision: Intra-assay (CV <5%) and inter-assay (CV <8%) for ELISA; POCT CV <10% (CLIA guidelines).
- Accuracy: Bias <±5% vs. reference method; linearity (R² >0.99) across measuring range.
- Sensitivity/Specificity: POCT: ≥95% clinical sensitivity, ≥98% specificity; ELISA: ≥98% sensitivity, ≥99% specificity (infectious disease assays).
- Analytical Specificity: No cross-reactivity with interfering substances (hemoglobin, bilirubin, lipids for serum/plasma samples).
Clinical Evidence: FDA rarely requires prospective clinical trials for Class II POCT/ELISA; retrospective clinical sample testing (50–200 samples) vs. predicate/reference standard is sufficient.
Quality System (QSR/21 CFR 820): ISO 13485 certification (mandatory for FDA inspections) + Design History File (DHF) with full design control recordsU.S. Food and Drug Administration.
Labeling: FDA-compliant IFU (Instructions for Use) with performance claims, limitations, and risk statements.

510(k) Review Timeline & Success Rates (2025 FDA Data)

Traditional 510(k): 90 FDA days (95% review completion target); success rate ~85%.
Special 510(k) (for QSR-compliant minor changes): 30 days; success rate ~92%.
Abbreviated 510(k) (for consensus standards): 60 days; success rate ~88%.

2.2 IVDR Essentials (EU 2017/746, Annex IX/X)

IVDR mandates CE marking via Notified Body (NB) audit for Class B/C/D IVDs, with a focus on clinical performance evaluation (PER) and post-market surveillance (PMS).

Key IVDRDR Requirements for POCT/ELISA

Technical Documentation (TD): Compile a TD file (Annex II) covering:
- Product description, design specs, and risk analysis (ISO 14971).
- Analytical performance data (same strictness as FDA; POCT/ELISA precision/sensitivity thresholds identical).
- Clinical Performance Report (CPR): For Class B POCT/ELISA, 50–300 clinical samples (EU population) vs. reference standard; for Class C, prospective clinical trials (≥500 samples) may be required.
- ISO 13485 quality system certificate (mandatory for NB audit).
Notified Body (NB) Audit: Select an EU-designated IVD NB (e.g., TÜV SÜD, BSI, SGS); audit timeline: 3–6 months (Class B).
CE Marking: After NB approval, affix CE mark + 4-digit NB number; register in EU’s EUDAMED database.
Post-Market Obligations:
- PMPF (Post-Market Performance Follow-Up): Annual performance monitoring for POCT/ELISA (5-year cycle).
- Vigilance Reporting: Report adverse events within 7 days (serious) or 15 days (non-serious).

IVDR Timeline & Costs (2025 Industry Data)

Class B POCT/ELISA: 6–9 months (NB audit + TD preparation); ~€80,000–€120,000 (excluding testing).
Class C POCT/ELISA: 12–18 months; ~€150,000–€250,000.

3. Step-by-Step Launch Roadmap (FDA 510(k) + IVDR for POCT/ELISA)

Phase 1: Pre-Development Regulatory Alignment (Months 1–3)

Classify Product: Confirm FDA Class II + IVDR Class B (default for POCT/ELISA).
Select Predicates & Standards:
- FDA: Identify 1–2 predicates (FDA 510(k) database); align with CLIA, ISO 15197 (POCT), ISO 9917 (ELISA).
- IVDR: Align with ISO 13485, ISO 14971, EN 62304 (software).
Quality System Setup: Implement ISO 13485 (gap analysis → certification; 2–3 months).
Risk Management: Conduct ISO 14971 risk analysis (POCT: user error risk; ELISA: reagent stability risk).

Phase 2: Product Development & Analytical Validation (Months 4–8)

Design Controls: Document DHF (design inputs/outputs, verification/validation) per 21 CFR 820 (FDA) + IVDR Annex IIU.S. Food and Drug Administration.
Analytical Testing (POCT/ELISA Critical):
- Precision/accuracy/linearity/specificity testing (GLP-compliant lab).
- Stability testing: POCT (12–24 months shelf life); ELISA (18–36 months reagent stability).
Clinical Sample Testing:
- FDA: 50–200 retrospective clinical samples (U.S. population) vs. predicate.
- IVDR: 50–300 retrospective clinical samples (EU population) vs. reference standard.

Phase 3: Regulatory Submission (Months 9–12)

FDA 510(k) Submission

Compile 510(k) dossier: SE summary, performance data, DHF excerpts, labeling, ISO 13485 certificate.
Submit via FDA eSubmitter (ESG portal); pay user fee (~$15,000 for small businesses).
Respond to FDA queries (average 1–2 rounds; 30 days per response).

IVDR Submission

Compile TD file (Annex II) + CPR + ISO 13485 certificate.
Submit to selected NB; undergo document review + on-site audit (manufacturing facility).
Resolve NCs (non-conformities); obtain NB CE certificate.

Phase 4: Post-Clearance Launch & Compliance (Months 13+)

FDA: Receive 510(k) clearance letter; register facility + list device in FDA’s GUDID database.
EU: Affix CE mark; register in EUDAMED; prepare PMPF plan.
Manufacturing: Scale production under ISO 13485; maintain DHF/DMF (Device Master File)U.S. Food and Drug Administration.
Surveillance: Conduct annual PMS (FDA) + PMPF (IVDR); update labeling as needed.

4. POCT vs. ELISA: Unique Compliance Challenges & Mitigations

4.1 POCT-Specific Challenges

User Error Risk: High for untrained users (e.g., home POCT). Mitigation: Simplify IFU; add visual prompts; include user testing data in 510(k)/IVDR submissions.
Lateral Flow Assay (LFA) Consistency: Lot-to-lot variability in membrane/reagent quality. Mitigation: Strict incoming material QC; 100% lot release testing (precision/sensitivity).
Rapid Result Claims: POCT claims “10-minute results” require validation. Mitigation: Time-to-result testing (n=50); include data in labeling.

4.2 ELISA-Specific Challenges

Reagent Stability: ELISA kits require cold chain storage (2–8°C). Mitigation: Stability testing under accelerated conditions (37°C for 4 weeks); include shipping/storage instructions in IFU.
High Sensitivity Requirements: ELISA claims “pg/mL detection” require rigorous linearity. Mitigation: Serial dilution testing (5–7 points); R² >0.99 mandatory.
Microplate Consistency: Well-to-well variability affects results. Mitigation: QC for microplates; intra-assay CV <5% acceptance threshold.

5. Critical Compliance Checklists (FDA 510(k) + IVDR)

✅ FDA 510(k) Checklist (POCT/ELISA)

Predicate device identified (510(k) number + clearance date)
Analytical performance data (precision/accuracy/sensitivity/specificity) completed
50–200 retrospective clinical samples tested vs. predicate
ISO 13485 certificate (valid, no major NCs)U.S. Food and Drug Administration
DHF with full design control recordsU.S. Food and Drug Administration
FDA-compliant IFU (performance claims, limitations, risk statements)

✅ IVDR Checklist (Class B POCT/ELISA)

Technical Documentation (Annex II) complete
Clinical Performance Report (CPR) with 50–300 EU clinical samples
ISO 13485 certificate (NB-recognized)
Risk analysis (ISO 14971) + risk control measures documented
EUDAMED registration completed post-CE marking
PMPF plan drafted (annual performance monitoring)

6. Conclusion & Strategic Recommendations

Launching POCT/ELISA IVD products under FDA 510(k) and IVDR compliance demands early regulatory alignment, rigorous analytical/clinical testing, and robust quality systems (ISO 13485). For most POCT/ELISA products, the Class II (FDA) + Class B (IVDR) pathway is optimal, with a total timeline of 12–15 months and costs of $100,000–$200,000 (excluding manufacturing).

Strategic Recommendations for IVDCDMO Clients

Leverage CDMO Expertise: Partner with an ISO 13485-certified IVD CDMO (like IVDCDMO) for end-to-end support: assay development, GMP manufacturing, regulatory dossier preparation, and NB/FDA liaison.
Harmonize Data Early: Design analytical/clinical studies to satisfy both FDA and IVDR requirements (e.g., include both U.S. and EU clinical samples) to reduce redundant work.
Prioritize Post-Market Compliance: Allocate resources for PMS (FDA) and PMPF (IVDR) to avoid non-compliance risks (e.g., FDA warning letters, EU CE mark suspension).

By following this roadmap and partnering with a specialized IVD CDMO, you can accelerate time-to-market, ensure full regulatory compliance, and capture share in the global POCT/ELISA diagnostics market.

Author Profile

IVDCDMO Team: Written by the IVDCDMO technical and regulatory team, with expertise in diagnostic assay development, GMP manufacturing, ISO 13485 systems, and global IVD commercialization for biotech innovators worldwide.